Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$254.28 USD

254.28
516,638

+5.58 (2.24%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $254.09 -0.19 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (151 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Supriyo Bose headshot

5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes

by Supriyo Bose

MPLX, LDOS, JAZZ, FTNT and PPC are some of the stocks with high ROE to profit from as markets falter on tariff concerns.

Urmimala Biswas headshot

4 Top PEG Stocks Based on GARP Approach to Smart Investing

by Urmimala Biswas

Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.

Ekta Bagri headshot

HRMY Down 10.8% in Six Months: How Should You Play the Stock?

by Ekta Bagri

A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.

Zacks Equity Research

Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

JAZZ or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

by Zacks Equity Research

Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Zacks Equity Research

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

by Zacks Equity Research

NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.

Bryan Hayes headshot

Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025

by Bryan Hayes

Despite a correction to begin the year, there are a few pockets of the market that are working.

Zacks Equity Research

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

by Zacks Equity Research

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.